Insulin icodec

Tarlatamab (Imdelltra) is set to transform small cell lung cancer treatment, targeting DLL3-expressing cells and potentially becoming the standard of care for previously treated ES-SCLC.

Novartis' Fabhalta (iptacopan) demonstrated significant proteinuria reduction in the Phase III APPEAR-C3G trial, meeting its primary endpoint and supporting regulatory submissions.

The biopharmaceutical sector is showing signs of recovery, with a 2% rise in combined market capitalization among the top 20 global companies.

Eli Lilly's efsitora, a weekly insulin injection, demonstrated effectiveness comparable to daily insulin in Phase 3 trials for type 2 diabetes.

Eli Lilly's efsitora alfa, a once-weekly insulin, demonstrated non-inferiority to daily insulin in Phase 3 trials for type 2 diabetes, meeting its primary endpoint.